Etheldreda Nakimuli-Mpungu1, Colin M Smith, Kizito Wamala, James Okello, Josephine Birungi, Micheal Etukoit, Ramin Mojtabai, Jean B Nachega, Ofir Harari, Seggane Musisi, Edward J Mills. 1. From the Department of Psychiatry, College of Health Sciences (Nakimuli-Mpungu, Seggane), Makerere University, Kampala, Uganda; Departments of Medicine (Smith) and Psychiatry and Behavioral Sciences (Smith), Duke University Medical Center, Durham, North Carolina; Department of Psychology (Wamala), Center for Victims of Torture; Department of Mental Health, Faculty of Medicine (Okello), Gulu University, Gulu; The AIDS Support Organization (TASO) (Birungi, Etukoit), Kampala, Uganda; Department of Mental Health, Bloomberg's School of Public Health (Mojtabai), Johns Hopkins University, Baltimore, Maryland; Department of Epidemiology, Pittsburgh Graduate School of Public Health (Nachega), University of Pittsburgh, Pittsburgh, Pennsylvania; Stellenbosch Center for Infectious Disease, Department of Medicine (Nachega), Stellenbosch University, Stellenbosch, South Africa; Department of International Health, Bloomberg's School of Public Health (Nachega), Johns Hopkins University, Baltimore, Maryland; MTEK Sciences Inc (Harari), Vancouver, British Columbia; and Department of Clinical Epidemiology and Biostatistics (Mills), McMaster University, Hamilton, Ontario, Canada.
Abstract
OBJECTIVE: We aimed to determine the effect of group support psychotherapy (GSP) compared with group HIV education (GHE) on depression and HIV treatment outcomes 24 months after treatment. We further aimed to investigate the mediating role of depression and antiretroviral therapy (ART) adherence in the relationship between GSP and viral load suppression. METHODS: Thirty HIV clinics across three districts were randomly assigned to deliver either GSP or GHE for depression. Depression and optimal (≥95%) ART adherence was assessed at baseline and 6, 12, 18, and 24 months after treatment. Viral load was drawn from the medical charts at baseline and 12 and 24 months after treatment. Multilevel mixed-effects regression models and generalized structural equation modeling were used to estimate 24-month outcomes and mediation effects. RESULTS: Participants ( N = 1140) were enrolled from HIV clinics offering either GSP ( n = 578 [51%]) or GHE ( n = 562 [49%]). Fewer GSP than GHE participants met the criteria for depression at 24 months after treatment (1% versus 25%; adjusted odds ratio [aOR] = 0.002, 95% confidence interval [CI] = 0.0002-0.018). More GSP than GHE participants reported optimal (≥95%) ART adherence (96% versus 88%; aOR = 20.88, 95% CI = 5.78-75.33) and improved viral suppression (96% versus 88%; aOR = 3.38, 95% CI = 1.02-11.02). The indirect effects of GSP through sequential reduction in depression and improvement in ART adherence at 12 months may partially explain the higher viral suppression rates at 24 months in GSP than GHE groups. CONCLUSION: In settings where the HIV epidemic persists, depression treatment with GSP may be critical for optimal HIV treatment outcomes.Trial Registration: The Pan African Clinical Trials Registry, number PACTR201608001738234.
OBJECTIVE: We aimed to determine the effect of group support psychotherapy (GSP) compared with group HIV education (GHE) on depression and HIV treatment outcomes 24 months after treatment. We further aimed to investigate the mediating role of depression and antiretroviral therapy (ART) adherence in the relationship between GSP and viral load suppression. METHODS: Thirty HIV clinics across three districts were randomly assigned to deliver either GSP or GHE for depression. Depression and optimal (≥95%) ART adherence was assessed at baseline and 6, 12, 18, and 24 months after treatment. Viral load was drawn from the medical charts at baseline and 12 and 24 months after treatment. Multilevel mixed-effects regression models and generalized structural equation modeling were used to estimate 24-month outcomes and mediation effects. RESULTS: Participants ( N = 1140) were enrolled from HIV clinics offering either GSP ( n = 578 [51%]) or GHE ( n = 562 [49%]). Fewer GSP than GHE participants met the criteria for depression at 24 months after treatment (1% versus 25%; adjusted odds ratio [aOR] = 0.002, 95% confidence interval [CI] = 0.0002-0.018). More GSP than GHE participants reported optimal (≥95%) ART adherence (96% versus 88%; aOR = 20.88, 95% CI = 5.78-75.33) and improved viral suppression (96% versus 88%; aOR = 3.38, 95% CI = 1.02-11.02). The indirect effects of GSP through sequential reduction in depression and improvement in ART adherence at 12 months may partially explain the higher viral suppression rates at 24 months in GSP than GHE groups. CONCLUSION: In settings where the HIV epidemic persists, depression treatment with GSP may be critical for optimal HIV treatment outcomes.Trial Registration: The Pan African Clinical Trials Registry, number PACTR201608001738234.
Authors: Brian W Pence; Jon C Mills; Angela M Bengtson; Bradley N Gaynes; Tiffany L Breger; Robert L Cook; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Michael J Mugavero Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Etheldreda Nakimuli-Mpungu; Kizito Wamala; James Okello; Stephen Alderman; Raymond Odokonyero; Ramin Mojtabai; Edward J Mills; Steve Kanters; Jean B Nachega; Seggane Musisi Journal: Lancet HIV Date: 2015-03-31 Impact factor: 12.767
Authors: Alexander C Tsai; Sheri D Weiser; Maya L Petersen; Kathleen Ragland; Margot B Kushel; David R Bangsberg Journal: Arch Gen Psychiatry Date: 2010-12
Authors: Adam W Carrico; Elise D Riley; Mallory O Johnson; Edwin D Charlebois; Torsten B Neilands; Robert H Remien; Marguerita A Lightfoot; Wayne T Steward; Lance S Weinhardt; Jeffrey A Kelly; Mary Jane Rotheram-Borus; Stephen F Morin; Margaret A Chesney Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: B J Feldman; R J Fredericksen; P K Crane; S A Safren; M J Mugavero; James H Willig; J M Simoni; I B Wilson; M S Saag; M M Kitahata; H M Crane Journal: AIDS Behav Date: 2013-01